Invented by Fernand Labrie, MYRIEL PHARMACEUTICALS, LLC

The market for pharmaceutical compositions has been steadily growing over the years, driven by advancements in medical research and an increasing demand for effective treatments. Pharmaceutical compositions refer to the combination of active pharmaceutical ingredients (APIs) with other substances to create a final product that can be administered to patients. One of the key factors driving the growth of this market is the rising prevalence of chronic diseases such as cancer, diabetes, and cardiovascular disorders. As the global population continues to age and lifestyles become more sedentary, the incidence of these diseases is expected to increase. This has created a need for innovative pharmaceutical compositions that can effectively treat these conditions and improve patient outcomes. Additionally, advancements in technology and drug delivery systems have played a crucial role in expanding the market for pharmaceutical compositions. Novel drug delivery methods such as transdermal patches, inhalers, and sustained-release formulations have made it easier for patients to adhere to their medication regimens. This has not only improved patient compliance but also increased the demand for pharmaceutical compositions that can be administered through these innovative delivery systems. Furthermore, the increasing focus on personalized medicine has also contributed to the growth of the pharmaceutical compositions market. Personalized medicine involves tailoring treatments to individual patients based on their genetic makeup, lifestyle, and other factors. This approach has gained traction in recent years as it offers the potential for more targeted and effective therapies. Pharmaceutical compositions that can be customized to meet the specific needs of patients are therefore in high demand. The market for pharmaceutical compositions is also being driven by the growing investment in research and development (R&D) by pharmaceutical companies. These companies are constantly striving to develop new and improved formulations that offer enhanced therapeutic benefits. The development of innovative pharmaceutical compositions requires significant investment in R&D, clinical trials, and regulatory approvals. However, the potential for high returns on investment has encouraged pharmaceutical companies to invest in this market. Moreover, the increasing focus on preventive healthcare and wellness has created opportunities for pharmaceutical compositions that can be used for disease prevention and health promotion. This includes the development of vaccines, nutritional supplements, and other preventive medications. The market for these types of pharmaceutical compositions is expected to witness significant growth in the coming years as governments and healthcare organizations prioritize preventive healthcare strategies. In conclusion, the market for pharmaceutical compositions is experiencing steady growth due to various factors such as the rising prevalence of chronic diseases, advancements in drug delivery systems, the focus on personalized medicine, and increased investment in R&D. As the demand for effective treatments continues to rise, pharmaceutical companies are likely to invest more in developing innovative compositions that can cater to the evolving needs of patients. This market presents immense opportunities for growth and innovation, ultimately leading to improved healthcare outcomes for patients worldwide.

The MYRIEL PHARMACEUTICALS, LLC invention works as follows

The invention discloses “new methods for treating or decreasing the likelihood of developing symptoms or diseases associated with menopause in postmenopausal woman, including osteoporosis and vaginal dryness, as well as hypogonadism and decreased libido. Other symptoms include hot flashes and loss of muscle mass. Said method comprising novel ways of administering and dosing dehydroepiandrosterone (DHEA) in order to take advantage of positive androgenic effects in the vaginal layers lamina propia and/or the layer muscularis, without undesirably causing systemic estrogenic effects in order to avoid the risk of breast and uterine cancer. “Pharmaceutical compositions useful for the invention include active ingredient(s).

Background for Pharmaceutical compositions


Example 1

Clinical Trail ERC-213

DHEA bioavailability following administration of vaginal suppositories to postmenopausal women with vaginal atrophy

Example 2

Bioavailability and Metabolism of Oral and Percutaneous Dehydroepiandrosterone in Postmenopausal Women

1. Introduction

2. “2.

3. “3.

5. “5.

6. Results


Example 3

Clinical Trail ERC 210

Intravaginal DHEA: Physiological Treatment of Vaginal Atrophia

Subjects & Methods

Vaginal ph & Cytology

Endometrial Biospy

Vaginal Examination

Vaginal secretions

Click here to view the patent on Google Patents.